Orientation-specific signalling by thrombopoietin receptor dimers.
Ligand binding to the thrombopoietin receptor is thought to stabilize an active receptor dimer that regulates megakaryocyte differentiation and platelet formation, as well as haematopoietic stem cell renewal.
Smith, Steven O +19 more
core +1 more source
Background: Inherited thrombocytopenias (ITs) are a group of rare disorders characterized by low platelet counts and variable bleeding risk. Surgical procedures in these patients often require transient platelet elevation.
Miguel de Oliveira +3 more
doaj +1 more source
Immune thrombocytopenia secondary to primary cytomegalovirus infection after renal transplantation treated with a thrombopoietin receptor agonist: a case report. [PDF]
Takehara T +9 more
europepmc +1 more source
Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial. [PDF]
Wan Z, Chen M, Han B.
europepmc +1 more source
Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review. [PDF]
Teekaput C +7 more
europepmc +1 more source
Background Nintedanib is a primary antifibrosing medication available for idiopathic pulmonary fibrosis, systemic sclerosis-interstitial lung disease, and progressive pulmonary fibrosis, with scattered report of drug-induced thrombocytopenia. Case report
Xinxin Zhang +4 more
doaj +1 more source
Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. [PDF]
Lozano ML +20 more
europepmc +1 more source
Background Immune thrombocytopenia (ITP) and antiphospholipid syndrome (APS) are autoimmune disorders that may coexist, creating a challenging clinical scenario characterised by bleeding risk alongside paradoxically increased thrombotic risk ...
Priyanta Banerjee +5 more
doaj +1 more source
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. [PDF]
Mei H +38 more
europepmc +1 more source
Case Report: Prolonged thrombocytopenia after chemotherapy in solid tumors requiring long-term thrombopoietin receptor agonist support: a five-patient case series. [PDF]
Wang S, Yu Y, Zhang L, Liu Q.
europepmc +1 more source

